Hemostatic material, hemostatic gauze and preparation method thereof

Abstract

The invention discloses a hemostatic material, hemostatic gauze and a preparation method thereof, and belongs to the technical field of hemostasis. The hemostatic material comprises a multi-element metal organic framework material, the hemostatic gauze is gauze loaded with the hemostatic material; the hemostatic material is obtained by coordination of metal ions or metal ion clusters and ligands. The metal ions comprise aluminum ions and iron ions, and the ligands comprise multi-element ligands; through cooperation of two doped metal ions, multistage hydrophilic sites are constructed, and the hemostatic behavior of the hemostatic material is regulated and controlled; through matching of multi-element ligands, the pore structure of the hemostatic material is regulated and controlled, the water adsorption kinetics of the hemostatic material is improved, and the water adsorption capacity of the hemostatic material is improved. The hemostatic material and the hemostatic gauze have the characteristics of high hemostatic speed and good hemostatic effect. The preparation method has the characteristics of simplicity in operation and easiness in industrialization.

Description

Technical Field

[0001] This invention belongs to the field of hemostasis technology, specifically relating to a hemostatic material, hemostatic gauze, and its preparation method. Background Technology

[0003] Currently, commonly used hemostatic materials both domestically and internationally include organic polymer materials (such as chitosan, modified starch, oxidized cellulose, etc.), biologically derived materials (such as thrombin, fibrin, etc.), and inorganic mineral materials (such as montmorillonite, kaolin, zeolite, etc.). Among these, inorganic mineral materials have attracted significant market attention due to their low cost, good hemostatic effect, and stable material properties. When performing hemostasis, powdered or processed powdered inorganic mineral hemostatic materials need to be applied to the wound, but they cannot be used for auxiliary hemostatic operations such as pressure or bandaging. If the bleeding is heavy, the hemostatic powder is easily dispersed by the blood flow, significantly reducing its hemostatic effect. Furthermore, powdered hemostatic materials require postoperative cleaning, increasing the difficulty of the procedure and potentially causing secondary injury. To address these issues, researchers have combined hemostatic materials with medical gauze to create hemostatic gauze. For example, the clay-based hemostatic gauze Combat Gauze (US8114433B2, CN101541274B, and CN101687056B) developed by Z-Medica in the United States has been adopted by the US military due to its high hemostatic efficiency, ease of use, and portability, demonstrating significant effectiveness. Chinese patents (CN118873717A, CN116036343A, and CN115990284A) also disclose zeolite-based hemostatic gauze, aiming to improve hemostatic efficacy and product flexibility for applications involving significant bleeding, such as arterial bleeding and intra-abdominal bleeding. Compared to previous powder-based hemostatic materials, zeolite-based hemostatic gauze offers significant advantages in terms of ease of use and safety. However, because zeolite has a strong affinity for water, it releases a large amount of heat while absorbing water from the blood, causing the wound site to heat up and potentially leading to burns and other secondary injuries. While using pre-hydrated zeolite materials, such as Z-Medica's QuikClotACS+, can reduce temperature rise, it also negatively impacts hemostatic efficacy. To address the issue of excessive heat release during hemostasis caused by zeolite-based hemostatic materials, Chinese patents (CN107261199A, CN109999216A) have proposed compounding zeolite materials with other materials (such as macromolecular proteins like human collagen and graphene). The resulting composite hemostatic materials reduce the temperature rise problem associated with zeolite hemostasis to some extent, but also introduce other issues, such as increased cost, poor stability of the compounded materials, and poor storage life.

[0004] Metal-organic frameworks (MOFs) are characterized by their large specific surface area and easily tunable composition and structure. They are frequently used as antibacterial agents or carriers, and combined with other hemostatic materials for antibacterial and hemostatic purposes. For example, Chinese patents (CN120324671A, CN117258028A, CN119548665A, CN 117924537A) all disclose MOF composite materials, in which MOF materials are used as antibacterial agents, loaded or combined with other antibacterial agents and hemostatic materials to achieve antibacterial and hemostatic effects. Furthermore, specific MOF materials are also used for hemostasis. Chinese patent (CN119463202A) discloses a hemostatic material based on ZIF-8, which achieves hemostasis by controlling the morphology and structure of ZIF-8, exposing specific crystal planes ({110} and {100}), adsorbing and activating thrombin activity. To overcome the drawbacks of weak bonding and easy detachment between ZIF-8 powder and substrate materials, Chinese patent (CN117026631A) discloses an electrospun nanofiber membrane with in-situ loaded ZIF-8. However, hemostatic materials or technologies based on ZIF-8 face the following problems: 1) The organic ligand of ZIF-8 is dimethylimidazole, which is biotoxic. Residual ZIF-8 is easily decomposed in the body or tissues, releasing biotoxic organic compounds that harm the body; 2) The hemostatic mechanism of ZIF-8 is not universal and cannot be extended to other MOF materials; 3) ZIF-8 used for hemostasis requires special control methods, and its synthesis and preparation technology is demanding. Chinese patent (CN115869460A) discloses a nanogel self-adhesive powder for wound antibacterial and hemostatic purposes. This nanogel self-adhesive powder has a three-layer structure: a core material as an antibacterial agent, a highly biosafe Mg-MOF intermediate layer, and a self-adhesive hydrogel outer layer. In this process, the hydrogel absorbs a large amount of water from the blood, playing a major role in hemostasis. Mg-MOF, acting as a carrier for antibacterial agents, interacts with water in the blood and decomposes to produce gallic acid, which has a certain hemostatic effect. However, Mg-MOF has weak hemostatic efficacy and, when used alone, lacks the ability to rapidly stop bleeding. Furthermore, the preparation process of this nanogel self-adhesive powder is complex and not easily suitable for industrial application. Summary of the Invention

[0005] To address the aforementioned problems with existing hemostatic materials, this invention discloses a novel hemostatic material, hemostatic gauze, and its preparation method. The hemostatic material disclosed in this invention possesses abundant hydrophilic sites and a large specific surface area, enabling it to absorb a large amount of water in a short time and concentrate clotting factors (platelets, fibrinogen) in the blood, thereby achieving rapid hemostasis. The hemostatic gauze obtained from this material exhibits excellent hemostatic effect and a simple preparation method.

[0006] To achieve the above objectives, the present invention adopts the following technical solution.

[0007] This invention first provides a hemostatic material obtained by coordination of a metal ion or a cluster of metal ions with an organic ligand; the metal ion includes aluminum ions and iron ions. Further, the ligand includes ligand A and ligand B; wherein ligand A is selected from one or more of terephthalic acid, isophthalic acid, trimesic acid, fumaric acid, 3,5-pyrazoledicarboxylic acid, 2,5-furandicarboxylic acid, or their salts or derivatives; and ligand B is selected from one or more of acetic acid, propionic acid, butyric acid, valeric acid, benzoic acid, caffeic acid, succinic acid, glutaric acid, adipic acid, or their salts or derivatives.

[0008] Furthermore, the preparation method of the hemostatic material includes the following steps: 1) Dissolve aluminum salt and iron salt in a certain amount of solvent to obtain precursor solution A; 2) Ligand A and basic auxiliaries are dissolved in a solvent to obtain precursor solution B; 3) Ligand B and basic auxiliaries are dissolved in a solvent to obtain precursor solution C; 4) Mix precursor solution A, precursor solution B and precursor solution C evenly and react them at a certain temperature for a certain time; 5) Collect the reaction products, clean them with a cleaning agent, and dry them to obtain the hemostatic material.

[0009] Further, the molar ratio of the total amount of metal ions in the aluminum and iron salts, the total amount of organic ligand A and organic ligand B, and the total amount of alkaline auxiliaries in precursor solution B and precursor solution C is 1:(0.5-5):(2-6); wherein the molar ratio of aluminum ions to iron ions is Al:Fe = 1:0-1 (excluding 0); the molar ratio of ligand A to ligand B is 1:0.05-4; the solvent is selected from one or more of water, methanol, ethanol, N,N-dimethylformamide, N,N-diethylformamide, and N,N-dimethylacetamide; the alkaline auxiliaries are selected from one or more of sodium hydroxide, potassium hydroxide, ammonia, amines, and N,N-dimethylformamide.

[0010] Furthermore, the reaction temperature in step (4) is room temperature to 150°C, and the reaction time is 1-24 h.

[0011] Furthermore, the cleaning agent is selected from one or more mixtures of water, alcohols, acetone, dimethyl sulfoxide, N,N-dimethylformamide, dichloromethane, and liquid carbon dioxide.

[0012] Furthermore, the drying process described in step (5) involves a drying temperature of 60-120°C and a drying time of 1-12 h.

[0013] The present invention also provides a hemostatic gauze, which comprises a flexible matrix, a hemostatic active ingredient, and a binder. The hemostatic active ingredient comprises at least one hemostatic material as described above.

[0014] Furthermore, the hemostatic active ingredient also includes additives, which are one or more of antibacterial agents, anti-inflammatory agents, analgesics, and anti-allergic agents.

[0015] Furthermore, the flexible substrate is in the form of a fabric, including one or more of cotton yarn, blended yarn, and non-woven yarn.

[0016] Furthermore, the adhesive is selected from one or more of polyvinylidene fluoride, sodium carboxymethyl cellulose, polyvinyl alcohol, polyethylene oxide, polyacrylic acid, polymethyl methacrylate, styrene-butadiene rubber, styrene-butadiene latex, pure acrylic rubber, styrene-acrylic rubber, chloroprene latex, chitosan, starch, guar gum, and gelatin.

[0017] Furthermore, the preparation method of the hemostatic gauze includes any one of the following methods: scraping coating, roller coating, spraying coating, spin coating, impregnation, pressure filtration, vacuum filtration, casting, and hot pressing.

[0018] The present invention also provides a method for preparing the above-mentioned hemostatic gauze, wherein the preparation method adopts an impregnation method, and the specific steps are as follows: 1) Preparation of slurry: Add appropriate amounts of thickener, dispersant, wetting agent, hemostatic active ingredient and binder to water, stir thoroughly to obtain a uniformly dispersed hemostatic slurry; 2) Coating the substrate: Immerse the selected flexible substrate in the plasma-stopping material obtained in step 1) and keep it for a certain period of time to allow it to be fully loaded; 3) Drying: The gauze loaded with hemostatic active ingredients obtained in step 2) is dried at a set temperature and time to obtain the hemostatic gauze.

[0019] Furthermore, thickeners, dispersants, and wetting agents can be added according to the state of the slurry.

[0020] Further, the hemostatic active ingredient accounts for 1%-10% of the weight of the slurry; preferably, the hemostatic active ingredient accounts for 2.5%-5% of the weight of the slurry.

[0021] Further, the mass ratio of the adhesive to the hemostatic active ingredient is 0.5-1.5:1; preferably, the mass ratio of the adhesive to the hemostatic active ingredient is 0.8-1:1.

[0022] Furthermore, the drying temperature range is 50℃-150℃, and the drying time range is 2-24 h.

[0023] Beneficial effects: 1) The hemostatic material is a multi-metal-organic framework material, and the selected metal ions and organic ligands have good biocompatibility and high safety in use; 2) By doping with different proportions of metal ions (Al... 3+ / Fe 3+ The combination of different organic ligands forms hydrophilic sites with different adsorption capacities and regulates the pore structure of hemostatic materials, such as specific surface area, pore size, and pore volume. This enhances the ability of hemostatic materials to adsorb water in blood from both thermodynamic and kinetic perspectives, thereby regulating the hemostatic process of the hemostatic materials and achieving the goal of rapid hemostasis. 3) Compared with the in-situ synthesis method of preparing gauze loaded with hemostatic components, the preparation method of hemostatic gauze of the present invention has the characteristics of simple operation, short process flow, and easy industrialization. Detailed Implementation

[0024] The following embodiments further illustrate the content of the present invention, but should not be construed as limiting the present invention. All other contents obtained by making several equivalent improvements and simple modifications to the present invention without departing from the spirit and essence of the present invention are within the scope of the present invention. Unless otherwise specified, the technical means used in the embodiments are conventional means well known to those skilled in the art. Example 1

[0025] I. Preparation of hemostatic materials Dissolve 110 g of aluminum sulfate octahydrate and 0.60 g of ferric sulfate in 500 mL of deionized water and stir until homogeneous to obtain precursor solution A.

[0026] 35.8 g of fumaric acid and 34 g of sodium hydroxide solvent were dissolved in 400 mL of deionized water and stirred until homogeneous to obtain precursor solution B.

[0027] Dissolve 1.71 mL of acetic acid and 4 g of sodium hydroxide in 100 mL of deionized water and stir well to obtain precursor solution C.

[0028] Mix the precursor solutions A, B, and C prepared above and react at room temperature for 2.5 h.

[0029] The reaction product was collected by centrifugation and washed three times with deionized water and ethanol. Then it was placed in an oven and dried at 120°C for 1 hour to obtain the hemostatic material of this embodiment.

[0030] II. Preparation of hemostatic gauze 22.5 g of carboxymethyl cellulose, 79 g of ammonium salt solution of acrylate copolymer, 27 g of polyether modified organosilicon, 160 g of the hemostatic material prepared above, and 160 g of polyacrylic acid were added to 4500 g of water and stirred thoroughly to disperse them evenly, thus obtaining the hemostatic material.

[0031] Soak sterile gauze in the blood plasma obtained in step 1) for 4 hours.

[0032] The gauze loaded with hemostatic material obtained in step 2) was placed in a forced-air drying oven for drying at a temperature of 50°C for 24 hours to obtain the hemostatic gauze of this embodiment. Example 2

[0033] Replace the amount of acetic acid added in step 3) of the hemostatic material preparation process in Example 1 with 17.14 mL, while keeping the other steps unchanged. Example 3

[0034] Replace the amount of acetic acid added in step 3) of the hemostatic material preparation process in Example 1 with 68.6 mL, while keeping the other steps unchanged. Example 4

[0035] I. Preparation of hemostatic materials Dissolve 110g of aluminum sulfate octahydrate and 3.4g of ferric sulfate in 550 mL of deionized water and stir well to obtain precursor solution A.

[0036] Dissolve 28 g of isophthalic acid in 100 mL of N,N-dimethylformamide (DMF) and stir until homogeneous to obtain precursor solution B.

[0037] 1.71 mL of acetic acid was dissolved in 40 mL of DMF, which was used as both an alkaline auxiliary and a solvent. The mixture was stirred until homogeneous to obtain precursor solution C.

[0038] Precursor solutions A, B, and C were mixed and placed in a reaction vessel, and reacted at 135°C for 24 h.

[0039] The reaction product was collected by centrifugation and washed three times with deionized water and ethanol. Then it was placed in an oven and dried at 60°C for 12 hours to obtain the hemostatic material of this embodiment.

[0040] II. Preparation of hemostatic gauze 1) Add 22.5 g of carboxymethyl cellulose, 79 g of ammonium salt solution of acrylate copolymer, 27 g of polyether modified organosilicon, 200 g of the hemostatic material prepared above, and 200 g of polyacrylic acid to 4500 g of water, stir thoroughly to disperse evenly and obtain hemostatic plasma.

[0041] 2) Soak sterile gauze in the blood plasma obtained in step 1) for 2 hours.

[0042] 3) Place the gauze loaded with blood-stopping material obtained in step 2) into a forced-air drying oven for drying at 120°C for 4 hours. Example 5

[0043] In Example 4, the amounts of aluminum sulfate octahydrate and ferric sulfate added in step 1) of the hemostatic material preparation process were replaced with 104 g and 6.7 g, respectively, while the remaining steps remained unchanged. Example 6

[0044] In Example 4, the amounts of aluminum sulfate octahydrate and ferric sulfate added in step 1) of the hemostatic material preparation process were replaced with 92.5 g and 13.5 g, respectively, while the remaining steps remained unchanged. Example 7

[0045] In Example 4, the amounts of aluminum sulfate octahydrate and ferric sulfate added in step 1) of the hemostatic material preparation process were replaced with 58 g and 33 g, respectively, while the remaining steps remained unchanged. Example 8

[0046] In Example 4, the amount of hemostatic material added in step 1) of the hemostatic gauze preparation process is replaced with 250 g, while the other steps remain unchanged. Example 9

[0047] In Example 4, the amount of hemostatic material added in step 1) of the hemostatic gauze preparation process is replaced with 100 g, and the amount of adhesive added is replaced with 150 g, while the other steps remain unchanged.

[0048] Comparative Example 1 Commercial zeolite hemostatic gauze.

[0049] Comparative Example 2 Blank experiment: blank gauze without any hemostatic components loaded.

[0050] The embodiments provide preparation steps for the hemostatic materials and hemostatic gauze, but these steps should not be construed as limiting the invention. In actual preparation, the preparation parameters can be adjusted appropriately based on the specific synthesis conditions. For example, the types and amounts of thickeners, dispersants, and wetting agents can be selected according to the specific state of the slurry; the types and amounts of binders can be adjusted within the scope of the technical solution of this invention.

[0051] The hemostatic material of this invention achieves rapid hemostasis by adsorbing water from the blood, concentrating hemostatic factors in the blood, and accelerating the body's hemostasis process. The hemostatic material prepared in this invention is a multi-element metal-organic framework material, obtained by coordinating aluminum and iron ions with multiple ligands. Considering that both Al and Fe are elements with high biocompatibility, they can be applied in the field of hemostasis. The differences in their ionic radii, charge densities, electronic configurations, and polarization abilities lead to different adsorption capacities for water molecules. By doping with different proportions of metal ions (Al... 3+ / Fe 3+ This invention constructs multi-level hydrophilic sites to regulate the water adsorption behavior of hemostatic materials, thereby controlling their hemostatic performance. Besides metal doping, the invention also utilizes a rational combination of multiple organic ligands to regulate the pore structure of the hemostatic material, such as specific surface area, pore size, and pore volume, improving the water adsorption kinetics and increasing the water adsorption capacity. In summary, this invention's hemostatic material can regulate the water adsorption behavior of hemostatic materials from both thermodynamic and kinetic perspectives, thus influencing hemostatic performance.

[0052] To further illustrate the effectiveness of the above-mentioned control methods, the hemostatic materials prepared in each embodiment are compared with the original metal-organic framework material without control (see Table 1). The results show that the specific surface area (BET) and pore volume of the obtained hemostatic materials are improved after metal doping and regulation with multiple organic ligands. A higher BET value indicates more water adsorption sites, and a larger pore volume indicates a greater maximum water adsorption capacity. By increasing the specific surface area and pore volume of the material, the water adsorption capacity of the hemostatic material can be further enhanced, thereby achieving rapid concentration of hemostatic factors in the blood, accelerating the hemostasis process, and reducing bleeding.

[0053] Table 1. Comparison of BET and pore volume between the hemostatic materials and the corresponding unregulated metal-organic framework materials in the examples. Material Name organic ligands <![CDATA[BET / m 2 / g]]> <![CDATA[Pore volume / cm 3 / g]]> Example 1 MIL-53(Al / Fe) fumaric acid, acetic acid 1078 1.15 Example 2 MIL-53(Al / Fe) fumaric acid, acetic acid 1120 0.96 Example 3 MIL-53(Al / Fe) fumaric acid, acetic acid 1140 1.12 Unregulated MIL-53(Al) fumaric acid 1044 0.84 Example 4 CAU-10-H(Al / Fe) isophthalic acid, acetic acid 570 0.38 Example 5 CAU-10-H(Al / Fe) isophthalic acid, acetic acid 650 0.44 Example 6 CAU-10-H(Al / Fe) isophthalic acid, acetic acid 580 0.45 Example 7 CAU-10-H(Al / Fe) isophthalic acid, acetic acid 550 0.47 Unregulated CAU-10-H(Al) isophthalic acid 530 0.25 Rat tail clipping hemostasis experiment: This experiment was conducted to verify the hemostatic effect of the hemostatic material of the present invention on chronic bleeding. The experimental process and results are recorded in detail below.

[0054] Husbandry conditions: The testing process was conducted in a barrier system laboratory (air cleanliness ≤ 10,000, air exchange rate 10-20 times / hour, temperature 20-26℃, daily temperature difference ≤ 3℃, relative humidity 40-70%), with a 12-hour light and 12-hour dark cycle. The animals were given an acclimatization period of one week, ensuring sufficient food and water.

[0055] Tail clipping for hemostasis: After anesthetizing each rat with isoflurane inhalation, the tail clipping point was marked 3 cm from the tip. After disinfection with povidone-iodine, the tail was cut off at the marked point, and the rat was allowed to bleed naturally into the bottle. Hemostatic gauze was placed inside the bottle beforehand to ensure full contact between the bleeding site and the gauze. The bleeding time was 1 minute after each rat started bleeding, and the bottle weight was measured again after 1 minute to calculate the amount of blood loss for each rat.

[0056] Comparing the hemostatic gauze prepared in Example 1, Comparative Example 1, and Comparative Example 2, the results of the rat tail-cutting hemostasis experiment clearly show that the gauze obtained in Example 1 has the smallest area covered by blood, indicating that it has the best hemostatic effect. The amount of bleeding in each experimental process was obtained by weighing the sample bottles before and after hemostasis, as shown in Table 2. The hemostatic gauze obtained in Example 1 significantly reduced the amount of bleeding in rats, with a 41.3% reduction compared to the commercial zeolite hemostatic gauze in Comparative Example 1, and a 51.5% reduction compared to the blank gauze, demonstrating excellent hemostatic ability.

[0057] Table 2 Results of the rat tail-cutting hemostasis experiment Group Blood loss / g Example 1 0.2515±0.0415 Comparative Example 1 0.4281±0.1101 Comparative Example 2 0.5183±0.0292 Rabbit carotid artery hemostasis experiment: This experiment verifies the hemostatic effect of the hemostatic material of the present invention on acute bleeding. The experimental process and results are recorded in detail below.

[0058] Experimental subjects: New Zealand white rabbits; weight: 2.5-3.5 kg; feeding conditions: acclimatization feeding for 1 week; condition: healthy adults.

[0059] Preoperative preparation: Surgical incision: Make an incision of about 4 cm along the midline of the neck, bluntly dissect the subcutaneous tissue and muscles to expose the left common carotid artery. Free the artery for 2-3 cm, and use vascular clamps to block blood flow at both the proximal and distal ends.

[0060] Creating a bleeding model: Use microscissors to make a 1.5 mm longitudinal incision in the middle of the artery.

[0061] Simulate acute bleeding: Remove the vascular clamp, start the timer, and observe free bleeding for 30 seconds.

[0062] Grouping: Apply a pre-weighed test hemostatic gauze tightly to the bleeding point and apply constant pressure (200 g weight, applied vertically). Record the effective hemostasis time (the time from application of pressure to complete cessation of bleeding, not exceeding 300 s).

[0063] Bleeding volume calculation: The test gauze was immediately retrieved after hemostasis, weighed to calculate the amount of blood absorbed, and the gauze was photographed.

[0064] Comparing the hemostatic gauze prepared in Example 4, Comparative Example 1, and Comparative Example 2, the results of the rabbit carotid artery hemostasis experiment clearly show that the hemostatic gauze obtained in Example 4 has the smallest blood coverage area and the best hemostatic effect. The bleeding volume and hemostasis time for each experiment are shown in Table 3. As can be seen from the data in Table 3, compared to the commercial zeolite hemostatic gauze of Comparative Example 1, the bleeding volume of the hemostatic gauze prepared in Example 4 was reduced by 51.6%; compared to the blank gauze, the bleeding volume was reduced by 74.1%. The results indicate that even in the face of critical situations of massive arterial hemorrhage, the hemostatic gauze disclosed in this invention also possesses the ability to quickly stop bleeding, and can significantly reduce bleeding volume compared to commercially available inorganic hemostatic gauze.

[0065] Table 3. Results of bleeding volume in the rabbit carotid artery hemostasis experiment. Group Blood loss / g Example 4 0.246 Comparative Example 1 0.508 Comparative Example 2 0.949 In summary, by constructing a multi-level hydrophilic site and pore structure for the hemostatic material, the ability of the hemostatic material to adsorb water from blood is regulated, thereby improving the hemostatic performance of the material. Comparative analysis of test results for tail-cutting hemostasis in rats and carotid artery hemostasis in rabbits shows that the hemostatic material and gauze provided by this invention can address different bleeding scenarios, including chronic bleeding and acute bleeding (arterial bleeding). Furthermore, the hemostatic gauze preparation method of this invention has the advantages of simple operation and easy scale-up, possessing great commercial potential.

Claims

1. A hemostatic material, characterized by: The hemostatic material is formed by coordination of metal ions or clusters of the metal ions with organic ligands; the metal ions include aluminum ions and iron ions, and the organic ligands are polybasic ligands, i.e., at least containing two or more ligands.

2. A haemostatic material according to claim 1, characterised in that: The organic ligands include ligand A and ligand B; wherein the ligand A is selected from one or more of terephthalic acid, isophthalic acid, trimesic acid, fumaric acid, 3,5-pyrazole dicarboxylic acid, 2,5-furan dicarboxylic acid, or a salt thereof, or a derivative thereof; and the ligand B is selected from one or more of acetic acid, propionic acid, butyric acid, valeric acid, benzoic acid, caffeic acid, succinic acid, glutaric acid, adipic acid, or a salt thereof, or a derivative thereof.

3. A haemostatic material according to claim 2, characterised in that: In the hemostatic material, the molar ratio of aluminum ions to iron ions is 1:0-1 and does not contain 1:0; and the molar ratio of the ligand A to the ligand B is 1:0.05-4.

4. A method of preparing a haemostatic material according to any one of claims 1 to 3, characterised in that, The preparation method comprises the following steps: Step (1) dissolving aluminum salt and iron salt in a certain amount of solvent to obtain precursor solution A; Step (2) dissolving ligand A and basic auxiliary agent in a solvent to obtain precursor solution B; Step (3) dissolving ligand B and basic auxiliary agent in a solvent to obtain precursor solution C; Step (4) uniformly mixing the precursor solution A, the precursor solution B and the precursor solution C, and reacting under certain temperature conditions for a certain time; Step (5) collecting the reaction product, and performing cleaning and drying to obtain the hemostatic material.

5. The method of claim 4, wherein the hemostatic material is prepared by the steps of: The molar ratio of the total amount of metal ions in the aluminum salt and the iron salt, the organic ligand A and the organic ligand B, and the total amount of the basic auxiliary agent in the precursor solution B and the precursor solution C is 1:(0.5-5):(2-6); wherein the molar ratio of aluminum ions to iron ions is Al:Fe = 1:0-1 and does not contain 1:0; and the molar ratio of the ligand A to the ligand B is 1:0.05-4.

6. The method of claim 4, wherein the hemostatic material is prepared by the steps of: The basic auxiliary agent is selected from one or more of sodium hydroxide, potassium hydroxide, ammonia, amine, N,N-dimethylformamide; the reaction temperature of step (4) is room temperature-150°C, and the reaction time is 1-24 h.

7. A hemostatic gauze, characterized by: The hemostatic gauze is composed of a flexible matrix loaded with a hemostatic active ingredient and a binder, wherein the hemostatic active ingredient at least comprises the hemostatic material according to any one of claims 1-3.

8. The hemostatic gauze according to claim 7, characterized in that: The flexible matrix is in the form of cloth, including one or more of cotton gauze, blended gauze and non-woven gauze; the hemostatic active ingredient further comprises an additive, which is one or more of bacteriostatic agent, anti-inflammatory agent, analgesic agent and anti-allergic agent.

9. A method of manufacturing a haemostatic gauze according to claim 7 or 8, characterised in that: The preparation method comprises any one of blade coating, roller coating, spraying, spin coating, impregnation, pressure filtration, suction filtration, casting and hot pressing.

10. The method of claim 9, wherein the hemostatic gauze is prepared by the steps of: The preparation method adopts the impregnation method, and the specific steps are as follows: Step 1) preparing a slurry: adding thickening agent, dispersing agent, wetting agent, hemostatic active ingredient and binder into water, and fully stirring to obtain a uniformly dispersed hemostatic slurry; Step 2) coating the matrix: immersing the selected flexible matrix in the hemostatic slurry obtained in step 1) to allow it to be fully loaded; 3) drying: drying the gauze loaded with the hemostatic active ingredient obtained in step 2) to obtain the hemostatic gauze.

11. The method of claim 10, wherein the hemostatic gauze is prepared by the steps of: The hemostatic active ingredient in the slurry is 1%-10% by weight; the mass ratio of the binder to the hemostatic active ingredient is 0.5-1.5:

1.

12. The method of claim 11, wherein: Further, the drying temperature ranges from 50°C to 150°C, and the drying time ranges from 2 to 24 hours.